<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="editorial" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-2175</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОТ РЕДАКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>FROM EDITOR</subject></subj-group></article-categories><title-group><article-title>Интервью в рамках цикла «Мнение лидеров»</article-title><trans-title-group xml:lang="en"><trans-title>The interview as part of the "Leadership Opinion" Series</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Редакционная</surname><given-names>статья</given-names></name><name name-style="western" xml:lang="en"><surname>Editorial</surname><given-names>Article</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2025</year></pub-date><volume>14</volume><issue>3</issue><fpage>18</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Редакционная с., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Редакционная с.</copyright-holder><copyright-holder xml:lang="en">Editorial a.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/2175">https://www.pharmjournal.ru/jour/article/view/2175</self-uri><abstract><p>В новом интервью из цикла «Мнение лидеров» мы поговорили с директором департамента специальных проектов холдинга «Нацимбио» Госкорпорации «Ростех» Татьяной Смоляновой и генеральным директором Центра Фармацевтической Аналитики Игорем Шохиным о том, как рождаются отечественные иммунобиологические препараты.</p></abstract><trans-abstract xml:lang="en"><p>In a new interview from the "Leadership Opinion" series, we spoke with Tatyana Smolyanova, Director of the Special Projects Department of the Nacimbio of the Rostec State Corporation, and Igor Shokhin, General Director of the Center of Pharmaceutical Analytics, about how domestic immunobiological drugs are born.</p></trans-abstract></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
